

Peanut Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/PB253C88BB27EN.html>

Date: May 2024

Pages: 133

Price: US\$ 6,499.00 (Single User License)

ID: PB253C88BB27EN

Abstracts

The 7 major peanut allergy markets reached a value of US\$ 445.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 939.2 Million by 2034, exhibiting a growth rate (CAGR) of 7.02% during 2024-2034.

The peanut allergy market has been comprehensively analyzed in IMARC's new report titled "Peanut Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Peanut allergy, also known as peanut hypersensitivity, is a food allergy in which the immune system mistakenly identifies peanut proteins as harmful and triggers an allergic reaction. This response occurs within minutes following direct or indirect contact with peanuts. Symptoms of the ailment can range from mild, such as itching and hives, to severe, including anaphylaxis, a life-threatening reaction that can cause difficulty breathing, swelling of the throat, and a drop in blood pressure. Individuals suffering from this illness may also experience digestive problems like stomach cramps, indigestion, diarrhea, nausea, vomiting, etc. The diagnosis of peanut allergy typically involves a combination of physical examination and underlying indications. Additionally, the doctor may investigate the patient's medical history, including a family history of allergies or any known allergies. A blood workup is utilized to monitor the antibodies in the bloodstream against allergies. The healthcare provider may perform certain assessment studies, such as skin prick tests and oral food challenges, to confirm a diagnosis in the patients.

The rising incidences of allergic reactions resulting from an overactive immune system against certain substances or foods are primarily driving the peanut allergy market. In addition to this, the increasing cases of impaired skin barriers due to atopic dermatitis, leading to exposure and penetration of food allergens, are also propelling the market

growth. Moreover, the widespread adoption of effective medications, such as epinephrine and antihistamines, to help manage symptoms during an allergic reaction is creating a positive outlook for the market. Apart from this, the escalating utilization of the radioallergosorbent test (RAST) to diagnose the ailment since it aids in identifying the amount of allergen-specific IgE antibodies in the blood is also bolstering the market growth. Furthermore, several key players are making substantial investments in developing novel therapies that target particular pathways to provide more effective relief of indications. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of oral immunotherapy, which is designed to offer durable desensitization to peanuts and reduce the risk of severe reactions, is expected to drive the peanut allergy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the peanut allergy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for peanut allergy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the peanut allergy market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the peanut allergy market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the peanut allergy market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current peanut allergy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the peanut allergy market performed so far and how will it perform in the

coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the peanut allergy market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the peanut allergy market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of peanut allergy across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of peanut allergy by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of peanut allergy by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with peanut allergy across the seven major markets?

What is the size of the peanut allergy patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of peanut allergy?

What will be the growth rate of patients across the seven major markets?

Peanut Allergy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for peanut allergy drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the peanut allergy market?

What are the key regulatory events related to the peanut allergy market?

What is the structure of clinical trial landscape by status related to the peanut allergy market?

What is the structure of clinical trial landscape by phase related to the peanut allergy market?

What is the structure of clinical trial landscape by route of administration related to the peanut allergy market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 PEANUT ALLERGY - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 PEANUT ALLERGY - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 PEANUT ALLERGY - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 PEANUT ALLERGY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 PEANUT ALLERGY - UNMET NEEDS

10 PEANUT ALLERGY - KEY ENDPOINTS OF TREATMENT

11 PEANUT ALLERGY - MARKETED PRODUCTS

- 11.1 List of Peanut Allergy Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Palforzia (Peanut Allergen Powder-dnfp]) - Nestl?
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 PEANUT ALLERGY - PIPELINE DRUGS

12.1 List of Peanut Allergy Pipeline Drugs Across the Top 7 Markets

12.1.1 CNP-201 - Cour Pharmaceutical

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status

12.1.2 Viaskin Peanut - DBV Technologies

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status

12.1.3 VE416 - Vedanta Biosciences

- 12.1.3.1 Drug Overview
- 12.1.3.2 Mechanism of Action
- 12.1.3.3 Clinical Trial Results
- 12.1.3.4 Safety and Efficacy
- 12.1.3.5 Regulatory Status

12.1.4 Omalizumab - Genentech/Novartis

- 12.1.4.1 Drug Overview
- 12.1.4.2 Mechanism of Action
- 12.1.4.3 Clinical Trial Results
- 12.1.4.4 Safety and Efficacy
- 12.1.4.5 Regulatory Status

12.1.5 PVX-108 - Aravax

- 12.1.5.1 Drug Overview
- 12.1.5.2 Mechanism of Action
- 12.1.5.3 Clinical Trial Results
- 12.1.5.4 Safety and Efficacy
- 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. PEANUT ALLERGY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. PEANUT ALLERGY – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 PEANUT ALLERGY - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Peanut Allergy - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Peanut Allergy - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Peanut Allergy - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Peanut Allergy - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Peanut Allergy - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Peanut Allergy - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Peanut Allergy - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Peanut Allergy - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Peanut Allergy - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Peanut Allergy - Market Size by Therapies

- 15.5.2.1 Market Size by Therapies (2018-2023)
- 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Peanut Allergy - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Peanut Allergy - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Peanut Allergy - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Peanut Allergy - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Peanut Allergy - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Peanut Allergy - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Peanut Allergy - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Peanut Allergy - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Peanut Allergy - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Peanut Allergy - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Peanut Allergy - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Peanut Allergy - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Peanut Allergy - Access and Reimbursement Overview

16 PEANUT ALLERGY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 PEANUT ALLERGY MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 PEANUT ALLERGY MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Peanut Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/PB253C88BB27EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PB253C88BB27EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

